Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study conducted in Bangladesh, researchers reported a higher prevalence of patchy alopecia in males, with non-cicatricial alopecia being more common, particularly alopecia areata, highlighting the need for accurate diagnosis to improve treatment and quality of life.

This study found that CD2 could be a potential new therapeutic target for treating patchy-type alopecia areata, suggesting the need for further research into its role.

In this study, researchers developed a nanocomposite microneedle patch containing copper/zinc dual-doped silica nanoparticles, which release substances to promote hair follicle regeneration by targeting various pathophysiological aspects of androgenic alopecia, presenting an effective anti-hair loss treatment strategy.

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

This study developed a gas-propelled microneedle patch with puerarin/quercetin nanoparticles, which demonstrated improved hair-regenerating effects in an androgenetic alopecia mouse model by increasing drug delivery, alleviating oxidative stress, promoting angiogenesis, and rejuvenating senescent cells.

This research highlights the potential of using nanomaterials with advanced reactive oxygen properties to target oxidative stress in hair follicle tissue, which is associated with androgenetic alopecia, addressing a gap in the current understanding of AGA treatments.

This study found that a microneedle patch with recombinant collagen XVII significantly improved hair coverage, follicle density, and angiogenesis in an androgenic alopecia mouse model, showing potential as a novel therapeutic strategy alongside established treatments like minoxidil.

This study aimed to develop a new transdermal patch for treating androgenetic alopecia using finasteride, combined with chemical permeation enhancers to improve drug delivery through the skin, but results of pharmacokinetics and pharmacodynamics evaluations are not reported.

This study on androgenetic alopecia in mice introduced a novel therapy combining microneedle patches and cold atmospheric plasma to enhance minoxidil delivery, leading to improved hair regeneration by boosting vascular growth and reshaping the hair follicle microenvironment.

This study demonstrates that a newly developed nanocomposite microneedle patch, releasing copper and zinc ions along with quercetin, effectively promotes hair follicle regeneration in androgenic alopecia by targeting various pathophysiological aspects of hair loss.

This study identified a new variety of central centrifugal cicatricial alopecia that includes patchy hair loss on the lateral and posterior scalp in African-American women, which could be misdiagnosed as traction alopecia without dermatoscopy and pathology.

This paper contains author contact information and disclosures without reporting new research findings or results.

In this case report, an adolescent girl with itchy alopecic patches showed hair regrowth and no new alopecia patches after 6 weeks of treatment, despite initial minimal improvement with oral doxycycline.

This article discusses the clinical features of tumid lupus erythematosus and emphasizes its importance as a differential diagnosis for noncicatricial alopecia, highlighting a case similar to alopecia areata without reporting new clinical results.

This case report highlights the importance of maintaining clinical suspicion for tinea incognito in patients with central centrifugal cicatricial alopecia who do not respond to typical corticosteroid treatments, as misdiagnosis can complicate treatment.

In this series, patients experienced alopecia with limited regrowth following mesotherapy, indicating possible lasting aesthetic consequences and suggesting the need for careful technique and close follow-up, as the condition might be underrecognized.

This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.

This article reports a case of neurodermatitis where a combination of intralesional steroids, oral doxepin, and psychotherapy resulted in complete symptom remission and hair regrowth, highlighting the importance of addressing emotional factors in treatment.

This case study reported that systemic lupus erythematosus (SLE) can initially present as patchy non-scarring alopecia, potentially misdiagnosed as alopecia areata, highlighting the importance of thorough examination.

This study reported a case where a 46-year-old woman developed alopecia without itching or pain on her scalp due to a cutaneous infection from *Mycobacterium abscessus*, which was resolved after three months of antibacterial treatment, resulting in new hair growth.

This study found that intralesional vitamin D3 achieved similar effectiveness to triamcinolone acetonide for treating patchy alopecia areata but was associated with fewer adverse effects and higher patient satisfaction.

In this study of 374 children with patchy hair loss in Delta Egypt, researchers found that most cases were due to non-scarring causes, particularly alopecia areata, followed by infectious causes like tinea capitis; these conditions were more prevalent in school-aged children from rural areas.

This study found that both intradermal BCG vaccine and intralesional triamcinolone acetonide were similarly effective for treating patchy alopecia areata, though intralesional triamcinolone was preferable due to fewer side effects associated with BCG vaccine.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

In this study, researchers found that patients with new-onset mild alopecia areata had higher levels of oxidative stress markers and reduced antioxidant levels compared to healthy individuals, suggesting that oxidative stress might play a role in the condition.

In this case report, researchers describe a 44-year-old woman with refractory patch alopecia areata achieving complete hair regrowth using a multi-modal approach of systemic and topical cholecalciferol with microneedling, although systemic vitamin D repletion remains a significant confounder.

In this study, both fractional carbon dioxide laser therapy and cryotherapy were found to be effective and safe for treating patchy alopecia areata, showing similar efficacy in improving hair growth compared to untreated control patches.

This article reviews alopecia areata treatments, noting varied outcomes, and reports no new clinical results.

In this clinical report, oriental medicine treatment was observed to regrow hair on alopecia areata patches and reduce lymphadenopathy symptoms in a 27-year-old patient.